REPH Historical Earnings image   This REPH historical earnings page last updated 3/2/2022
REPH Historical Revenue
PeriodHistorical Earnings DateGAAP
Q4 20213/1/20220.02B
Q3 202111/9/20210.02B
Q2 20218/9/20210.02B
Q1 20215/6/20210.02B
Q4 20202/26/20210.01B
Q3 202011/9/20200.02B
Q2 20208/10/20200.02B
Q1 20205/11/20200.02B
Q4 20193/4/20200.02B
Q3 201911/8/20190.03B
Q2 20198/8/20190.03B
Q1 20195/10/20190.03B
Q4 20182/19/201917.78M
Q3 201811/7/201818.28M
Q2 20188/7/201821.74M
Q1 20185/9/201819.54M
Q4 20172/27/201819.04M
Q3 201711/9/201717.11M
Q2 20178/10/201716.93M
Q1 20175/11/201718.74M
Q4 20163/6/201717.36M
Q3 201611/10/201616.95M
Q2 20168/11/201617.28M
Q1 20165/12/201617.74M
Q4 20153/24/201616.75M
Q3 201511/13/201516.54M
Q2 20158/14/201518.66M
Q1 20155/12/2015NA
Q4 20143/25/2015NA
Q3 201411/10/2014NA
Q2 20148/12/2014NA
Q1 20145/12/2014NA
REPH Historical Earnings EPS
Data adjusted for REPH split history

PeriodHistorical Earnings DateGAAP
Q4 20213/1/2022-0.040
Q3 202111/9/2021-0.070
Q2 20218/9/20210.030
Q1 20215/6/2021-0.230
Q4 20202/26/2021-0.480
Q3 202011/9/2020-0.090
Q2 20208/10/2020-0.250
Q1 20205/11/2020-0.330
Q4 20193/4/2020-0.380
Q3 201911/8/2019-0.17
Q2 20198/8/2019-0.12
Q1 20195/10/2019-0.09
Q4 20182/19/2019-0.52
Q3 201811/7/2018-0.57
Q2 20188/7/2018-0.56
Q1 20185/9/2018-0.58
Q4 20172/27/2018-1.14
Q3 201711/9/2017-0.43
Q2 20178/10/2017-0.43
Q1 20175/11/2017-0.38
Q4 20163/6/2017-0.73
Q3 201611/10/2016-0.45
Q2 20168/11/2016-0.74
Q1 20165/12/2016-0.64
Q4 20153/24/2016-0.64
Q3 201511/13/2015-0.22
Q2 20158/14/2015-0.15
Q1 20155/12/2015-0.48
Q4 20143/25/2015-0.40
Q3 201411/10/2014-0.55
Q2 20148/12/2014-0.32
Q1 20145/12/2014-3.29
Quotes delayed 20 minutes

Email EnvelopeFree REPH Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Recro Pharma (REPH) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

REPL Past Earnings
RETA Past Earnings
RGEN Past Earnings
RGLS Past Earnings
RGNX Past Earnings
RIGL Past Earnings
RLAY Past Earnings
RLMD Past Earnings
RLYB Past Earnings
RMD Past Earnings
What was the record high REPH historical earnings result?
In terms of earnings or revenue, what is the best REPH historical earnings result that Recro Pharma has ever posted, and when?

✔️Accepted answer: Within our data set, the highest REPH historical earnings result was set in Q2 2021, when Recro Pharma posted results of 0.030/share. The most successful revenue quarter within our data set was Q2 2019 when Recro Pharma reported revenue of 0.03B.

What was the lowest Recro Pharma historical earnings result?
In terms of top line revenue or bottom line earnings per share, what was the lowest REPH has reported, and when?

✔️Accepted answer: Within our data set, the lowest REPH historical earnings result was set in Q1 2014, when Recro Pharma posted results of -3.29/share. The smallest revenue quarter within our data set was Q1 2015 when Recro Pharma reported revenue of NA.

On this page we presented the REPH historical earnings date information for Recro Pharma. Reviewing that REPH Historical Earnings for the company, we see that the highest historical earnings result in our data set was in Q2 2021, when REPH posted gaap of 0.030/share. Meanwhile the lowest REPH historical earnings result was in Q1 2014, when REPH posted gaap of -3.29/share. Moving to Recro Pharmas historical revenue numbers, the largest revenue quarter in our data set was seen in Q2 2019 when REPH reported 0.03B in revenue, while the smallest revenue quarter was Q1 2015 when REPH reported NA in revenue.

For self directed investors doing their due diligence on REPH or any other given stock, their research can benefit from looking into all of the Recro Pharma historical earnings in our data set presented side by side on one page for ease of comparison. Reviewing this historical EPS information can help when projecting future earnings per share, as well as providing important context for pondering whether the historical earnings trajectory justifies the current stock value or not. That's why we bring you to make it more convenient for investors to look into Recro Pharma historical earnings, or the historical earnings information for any stock in our coverage universe. In your continued due diligence investigations, we hope you check out the further links included for historical PE studies, earnings surprises history as well as next earnings dates for REPH. Thanks for visiting, and the next time you need to research REPH historical earnings or those of another stock, we hope our site will come to your mind as your preferred historical earnings, revenue, and EPS research resource of choice.

Recommended: LH Historical Stock Prices, URBF Insider Buying, FENX Options Chain.


REPH Historical Earnings | | Copyright © 2020 - 2022, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.